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1. Introduction  
A broadly effective malaria vaccine is a missing component of the practical tools needed to 
control and eventually eliminate malaria. For more than 50 years malaria researchers have 
been searching for a strategy that provides long lasting protection against a broad range of 
parasite strains. Many different approaches have been tested including whole parasite and 
subunit vaccines composed of one or more parasite surface proteins that are naturally 
targeted by the host immune response.  
Candidates in the malaria vaccine pipeline include surface exposed proteins from each of 
the morphologically distinct developmental stages of the parasite lifecycle within the human 
host. Many of these antigens have undergone rigorous developmental and preclinical 
testing as subunit vaccines [1] but only a few have reached advanced clinical trials: one 
reason being a lack of funding to carry all promising vaccine candidates to trial [2]. For 
candidates that have reached Phase II clinical trials in malaria endemic areas, there has been 
variable success. This is not surprising given that the malaria parasite is a complex and 
rapidly evolving organism that can quickly adapt to its ever-changing environment and 
effectively evade human immune responses. Limited understanding of the precise 
mechanisms and minimal requirements for antimalarial immunity has also hampered 
vaccine progress [3]. Moreover, the high degree of diversity of parasite surface antigens 
[4] and the allelic-specificity of the immune response [5, 6] is likely to have contributed 
significantly to the variable success of malaria vaccines. However genetic diversity is 
often overlooked in vaccine design with most vaccines formulated on the basis of a single 
strain. It is now increasingly recognized that to be effective against the worldwide 
parasite population, a malaria vaccine may need to contain multiple variants of the target 
antigen [7]. 
Many studies have investigated the genetic diversity of vaccine antigens that are circulating 
in natural parasite populations but very little of this knowledge has been applied to malaria 
vaccine design. Typically, alleles from one or two reference strains (3D7 or FVO) are used in 
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vaccine formulations, but this only partially represents the diversity of alleles circulating in 
the parasite population (Figure 1 [8]). Moreover, if vaccine alleles are found at low 
frequencies, the power to measure the success of vaccine trials is limited. This chapter 
reviews the current state of knowledge of the genetic diversity of leading malaria vaccine 
candidates, including those for both major human malaria parasites, Plasmodium falciparum 
and Plasmodium vivax. We examine the relevance of this diversity to malaria vaccines 
currently in development and how to use this information in determining which alleles 
should be used to provide broad coverage against the majority of parasite strains. Using 
leading candidate vaccine antigens as examples, we outline how population genetic tools 
can be used to characterise genetic diversity and the distribution of alleles and to define 
potentially immunologically relevant subgroups of alleles and polymorphisms. Finally, we 
make recommendations for the design of the next generation of malaria vaccines. 
  
Fig. 1. Worldwide frequency of alleles represented in ten leading malaria vaccine candidates 
(adapted from [8]). MSP119 3D7 and FVO are being developed as a combination vaccine as 
well as in isolation.  
2. Malaria vaccines: A brief history 
2.1 Early studies 
The idea that a malaria vaccine might be possible was raised in the late 1800’s with the 
observations of Robert Koch during his expedition to the Melanesian Island of Papua New 
Guinea (PNG). He found that while local children frequently displayed symptoms of 
malarial disease and harboured parasites in their blood, adults remained relatively disease 
and parasite-free [9]. He also noted that Malay and Chinese workers that had recently 
immigrated to PNG became ill with malaria more often than their counterparts who had 
been in residence for longer periods of time. These observations form the basis for our 
contemporary understanding of the epidemiology of malaria and the theory that immunity 
to malaria is eventually acquired in areas where people are constantly exposed to infection. 
In his conclusions, Dr. Koch stated that it would be possible to vaccinate against malaria 
toxins (and therefore the symptoms caused by infection).  
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Some 60 years later, the feasibility of a human malaria vaccine received a boost when Sir Ian 
MacGregor demonstrated that immunity was conferred by transferring hyperimmune sera 
(IgG) from adults to at-risk African children [10]. Soon afterward, a team at New York 
University (NYU) including Ruth Nussenzweig and Jerome Vanderberg showed that mice 
could be vaccinated against malaria with irradiated Plasmodium bergei sporozoites [11]. In 
1973, Clyde and colleagues at the University of Maryland in collaboration with the NYU 
team demonstrated that infections of humans via the bite of irradiated sporozoite-positive 
mosquitoes protected against subsequent homologous challenge, thus providing the first 
real evidence that man could be vaccinated against P. falciparum malaria [12] and 
subsequently, against P. vivax [13]. Later work showed that this approach was also effective 
in protecting against heterologous strains of P. falciparum [14]. These studies demonstrated 
that a malaria vaccine could elicit sterile protective immunity, and provided the reagents 
and tools to identify molecules that were important immune targets, such as the 
circumsporozoite surface protein (CSP) [15]. Unfortunately, at the time it was impractical to 
vaccinate large numbers of people with irradiated sporozoites isolated from infected 
mosquitoes and attempts to culture sporozoites showed only limited success [16]. 
2.2 Subunit vaccines 
The increasing availability of molecular cloning and PCR techniques in the early 1980’s saw 
a major shift in focus to the development of synthetic “subunit” vaccines based on 
individual parasite proteins and peptides and the abandonment of whole-parasite 
approaches. Several teams around the world had identified parasite surface proteins as 
targets such as the sporozoite antigens: circumsporozoite surface protein (CSP) [15] and 
thrombospondin related antigen (TRAP, [17, 18]) ; Liver stage antigen 1 (LSA1,[19]); and the 
merozoite surface proteins, MSP1 [20], MSP2 [21], S-Antigen [22] and Apical Membrane 
Antigen 1 (AMA1, [23, 24]). Initial studies in animal models were promising but excitement 
began to wane as subunit vaccines showed only around half of the candidates had a 
protective effect in clinical trials. Of the eight malaria vaccine candidate antigens that have 
reached Phase II trials, only one, “RTS,S” which is based on CSP, has now been tested in 
Phase III clinical trials [25]. 
2.3 Whole parasite vaccines 
The malaria parasite is a complex organism with 3000 or so known proteins [26, 27] 
including a few hundred that are immunogenic surface antigens [28]. This makes it a 
formidable target and therefore a vaccine as complex as the parasite itself may be required 
to immunise against malaria [29]. Evidence that sporozoite vaccinees were resistant to both 
homologous and heterologous challenge [14] makes whole-parasite vaccination approaches 
an appealing option so long as technological challenges can be overcome. New techniques 
for mass-producing sporozoites are reportedly in development [30] and both irradiation [31] 
and genetically attenuated [32, 33] parasite vaccines are being tested. Low doses of blood 
stage parasites have been shown to induce T-cell mediated responses targeted at 
cytoplasmic proteins with high levels of sequence conservation [34]. In addition, chemically- 
and genetically-attenuated blood-stage parasites are being developed (personal 
communication M. Good, Griffith University and K. Evans, Walter and Eliza Hall Institute). 
Consequently, whole parasite approaches have been experiencing a renaissance and have 
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garnered much support from funding organisations [35]. As both subunit and whole 
parasite approaches are valid approaches [35, 36], they are being pursued in parallel. This 
review focuses primarily on the former approach. 
2.4 Malaria vaccine subclasses 
Malaria vaccines fall into three main classes based on the lifecycle stage that they target and 
their expected biological effects [37-39]. These include: 
i. Pre-erythrocytic vaccines – based on antigens on the surface of the sporozoite or liver 
stage parasites or whole parasite (sporozoite approaches). These vaccines are designed 
to target the pre-erythrocytic stages of the parasite lifecycle and therefore inhibit 
infection. 
ii. Blood stage vaccines – based on antigens on the surface of the blood stages such as the 
merozoite or intraerythrocytic stages or whole blood stage parasites. These disease-
blocking vaccines are designed to control parasitaemia by preventing invasion of 
uninfected erythrocytes (merozoite targets) or to control disease by preventing 
cytoadhesion (intraerythrocyte targets), which leads to pathogenesis.  
iii. Transmission blocking vaccines – based on antigens on the surface of the sexual stages, 
expressed either within the human host or anopheline vector. Known as transmission-
blocking vaccines because they are designed to elicit antibodies within the human host 
that will target gametocytes (transmission forms) or to be taken up in the mosquito 
blood meal to target parasite proteins within the mosquito midgut.  
Vaccine approaches currently being tested include individual candidates from a single 
lifecycle stage as well as combination vaccines formulated with targets from multiple 
lifecycle stages.  
3. Subunit vaccine candidate antigens 
The advent of recombinant DNA technology has greatly facilitated the development of 
subunit malaria vaccines by providing the tools with which to synthesise large amounts of 
parasite protein, and to disrupt gene expression for detailed functional characterisation [40-
42]. Preclinical development for many candidate antigens has been successful and Phase II 
clinical trials have proceeded for at least eight candidate antigens, with evidence of 
antimalarial efficacy for MSP2 [6], CSP [43, 44], MSP3 [45] and AMA1 [46].  
The release of the first full malaria genome sequence in 2002 allowed the systematic 
identification of novel malaria vaccine candidates amongst approximately 5300 genes. 
Genome wide screening for single nucleotide polymorphisms (SNPs) has been used to 
reveal loci under positive selection and therefore encoding proteins that may be targeted by 
the immune response [4, 47]. Proteomics approaches have characterised the “immunome” 
[48], and measured the abundance of parasite proteins on the parasite surface [49]. A 
pipeline of bioinformatic screens has also been used to identify surface proteins, gene 
knockouts and high-throughput immunological assays to identify novel surface antigens 
(e.g. [50]). In the last 10 years, the list of potential malaria vaccine candidates has rapidly 
expanded to encompass many antigens about which there is still much to be learnt. Targets 
that were discovered first are therefore further down the development pipeline rather than 
novel proteins that may ultimately be more successful.  
www.intechopen.com
 
Using Population Genetics to Guide Malaria Vaccine Design 
 
235 
Below, we describe the most developed malaria vaccine candidates for the two major 
malaria parasites, P. falciparum and P. vivax as well as some novel vaccine candidates that 
have recently been identified for P. falciparum. This is not a comprehensive listing, a 
complete list of preclinical, clinical and inactive or discontinued malaria vaccine projects 
can be found in the World Health Organisation’s Malaria Vaccine Rainbow Tables [51]. 
3.1 Plasmodium falciparum  
P. falciparum is responsible for most of the mortality and morbidity associated with malaria, 
with up to 1 million deaths and around 225 million clinical cases caused by this species [52]. 
It is the only major human malaria parasite for which an in vitro culture system is available 
thus making it more tractable for investigations to characterise molecular structure and 
function and interactions with its human and anophelene hosts. As a result, malaria 
research has focused on developing ways to combat this particular species with less focus on 
other human infecting malaria parasites. The number of well-developed P. falciparum 
vaccine candidates in advanced stages of clinical development reflects this bias and there are 
strong candidates for every stage of the P. falciparum lifecycle within the human host. Some 
of these are described in detail below. 
3.1.1 Circumsporozoite Protein (CSP)  
CSP, which is found in the outer sporozoite membrane, was shown to be a target of 
antibodies that prevented hepatocyte infection, thereby interrupting an obligatory stage in 
the parasite’s lifecycle [15]. Cloning of the CSP gene (amongst other antigens) opened the 
doors to mass production and it was hoped, a malaria vaccine [53]. CSP contains a central 
(NANP) repeat region containing B-cell epitopes flanked by non-repetitive sequences 
containing T-cell epitopes [53-55]. In 2004, a considerable protective effect was observed 
with a CSP-based vaccine known as RTS,S with 49% efficacy against severe malaria for a 
period of 18 months in children aged 1-4 years [44]. This vaccine is composed of the central 
repeat and the C-terminal regions of CSP isolated from the reference strain, 3D7, combined 
with a Hepatitis B surface antigen (which provides protection against Hepatitis B and 
therefore satisfies ethical requirements). Recently published data from a phase III trial 
including 6000 African children has shown a 50% reduction in clinical episodes and 35% 
reduction in severe disease in children aged 5-18 months [25]. Therefore, RTS,S is likely to be 
the first licensed malaria vaccine and should be available within the next few years [56]. 
Most would agree though that it is an important proof of principle rather than an end to the 
hunt for a vaccine. 
3.1.2 Thrombospondin Related Adhesion Protein (TRAP) 
TRAP also known as Sporozoite Surface Protein (SSP) [18, 57] is present within the 
micronemes of the sporozoite and is essential for gliding motility and host cell invasion in 
the mosquito and human pre-erythrocyte stages [58-60]. TRAP is also expressed in the blood 
stages though its function in this stage is not well understood [18, 57]. TRAP is a Type I 
transmembrane protein consisting of multiple adhesive domains and a central repeat region 
flanked by unique sequence. Anti-repeat monoclonal antibodies have been shown to at least 
partially inhibit sporozoite invasion in vitro [61] and potent T-cell responses have been 
identified in individuals vaccinated with irradiated sporozoites [62, 63] as well as people 
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who are naturally exposed to malaria [64]. TRAP is highly polymorphic [65] and has also 
been shown to be under strong diversifying selection suggesting that it is a natural immune 
target [66].  
Mapping of inhibitory epitopes has led to the development of the multiepitope (ME)-TRAP 
DNA vaccine, which contains 15 TRAP T-cell epitopes. The vaccine has been delivered 
using a prime-boost regime involving three doses of naked DNA or DNA fused to a viral 
vector, to produce potent T-cell responses in both animals and humans [67]. While safety 
and immunogenicity trials in the UK have shown promising results [68, 69], Phase II efficacy 
trials conducted in semi-immune adults in The Gambia and children in Kenya provided no 
evidence of protective efficacy [70-73]. 
3.1.3 Apical Membrane Antigen 1 (AMA1) 
AMA1 is an 83 kDa integral membrane protein expressed late in the asexual stages and 
found in the micronemes at the apical tip of merozoites [74]. Prior to schizont rupture the 
AMA1 prodomain is cleaved to reveal a 66 kDa protein containing three subdomains 
(domains I, II and III) defined by their disulfide bonds [24]. AMA1 then relocates to the 
parasite surface [75] where further processing during invasion leads to shedding of two 
fragments of 44 and 48 kDa whilst the 22kDa cytoplasmic tail remains in the membrane and 
is carried into the invaded erythrocyte [76, 77]. AMA1 is now known to function in 
formation of the tight junction through interactions with rhoptry neck proteins [78, 79]. This 
molecule is also expressed in sporozoites where it is involved in hepatocyte invasion [80]. 
Antibodies against AMA1 are found in people living in malaria endemic areas [81-83], and 
these have been shown to block the invasion process [84-86]. The potential of AMA1 as a 
malaria vaccine candidate has been demonstrated in rodent models of malaria with both 
strain-specific [87-89] and cross-protective [90] protection observed. High levels of 
polymorphism in AMA1 [8, 91, 92] due to strong balancing selection [93] has resulted in 
hundreds of distinct AMA1 haplotypes; this might indicate that the development of a 
broadly effective AMA1-based malaria vaccine will be difficult. However, little is known 
about the antigenic diversity of AMA1 and recent studies suggest that immunization with a 
small number of different alleles might give broad reactivity [94, 95]. The availability of a 3D 
structural model for AMA1 has greatly advanced our understanding of antibody inhibition 
of AMA1 function by demonstrating that several polymorphisms are found on the edge of a 
hydrophobic pocket within which it is thought the receptor binds [96, 97]. A cluster of 
polymorphisms in this region, known as the “C1L cluster” contributes to immune escape 
[97], but the importance of residues outside this cluster remains unclear [92].  
Vaccine candidates comprising full length AMA1 originating from the 3D7 strain alone 
(FMP2.1, [46] and in combination with FVO (AMA1-c1, [98]), have had variable success in 
Phase II efficacy trials. FMP2.1 demonstrated no efficacy using the primary endpoint of a 
clinical malaria episode, however when the secondary endpoint of clinical infections 
carrying the vaccine allele was defined, a substantial efficacy of 68% above that of the 
control was revealed [46]. The alternative vaccine candidate, AMA1-C1, showed no allele-
specific efficacy however the prevalence of the vaccine allele amongst the samples was so 
low that sample numbers precluded a proper assessment of any effect [98]. Additionally, the 
adjuvant used was alum, which is less potent. 
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Another approach for AMA1 that is being tested is a diversity-covering vaccine (PfAMA1 
DiCo) whereby 355 published sequences were aligned and common polymorphisms (i.e. 
those found in >16% of sequences) were used to design three synthetic constructs, which 
together encompass 97% of the sequence diversity [99]. So far there have not been any 
clinical trials however broader parasite growth inhibitory activity was observed in 
animals vaccinated with the DiCo mix than those vaccinated with native AMA1 from the 
FVO strain [99]. 
3.1.4 Merozoite Surface Protein 1 (MSP1) 
MSP1 is the most abundant and best studied of the P. falciparum merozoite surface antigens. 
The protein is synthesised as a 190-kDa-precursor protein that is cleaved into four fragments 
of 83, 30, 38, and 42 kDa [100]. These exist as a non-covalently associated complex tethered 
by a glycosylphosphatidylinositol (GPI) anchor at the C-terminal [101]. During erythrocyte 
invasion, the N-terminal fragments are shed when MSP142 undergoes a secondary 
processing event generating a further 33 kDa (MSP133) and 19 kDa fragment (MSP119) [102-
104] which facilitates parasite entry into the erythrocyte [105]. The MSP119 fragment is 
retained on the surface of the invading merozoite [106]. 
The C-terminal end of MSP1 is a leading malaria vaccine candidate. The MSP133 sequence is 
dimorphic, with diverse alleles clustering within the two families known as K1 and Mad20 
[107], however MSP119 is relatively conserved across the two allele families with six 
nonsynonymous SNPs that are commonly used to describe MSP119 haplotypes [108-113]. 
Within each of the allele-families, MSP133 also contains several single nucleotide 
polymorphisms (SNPs) and a 3 bp deletion [108, 111].  
The FMP1/ASO2A vaccine, which is formulated with the 3D7 allele of MSP142, has been 
tested in Phase II trials. The vaccine initially showed promise in safety and immunogenicity 
trials in 40 Malian adults, with responses generated to parasite clones carrying diverse 
MSP142 alleles (FVO and Camp/FUP) [114]. Phase II efficacy trials including 400 children in 
Western Kenya did not protect against infection or lower parasite densities, nor did it 
reduce clinical episodes [115]. Though the authors stated that the vaccine was no longer a 
promising vaccine candidate, this was without having investigated how many vaccinees 
were infected with the vaccine strain. In addition, high throughput genotyping studies in 
Mali have demonstrated that the 3D7 allele had a prevalence of only 16% [113]. A vaccine 
containing both MSP142 3D7 and FVO alleles fused together with conserved regions of MSP1 
is currently being tested [116].  
3.1.5 Merozoite Surface Protein 2 (MSP2) 
MSP2, a 45-52 kDa glycoprotein is tethered to the membrane a glycosylphosphatidylinosital 
(GPI) anchor and is the second most abundant protein (based on copy numbers) on the 
merozoite surface [49]. The protein consists of highly conserved N- and C-terminal ends 
flanking a highly polymorphic central repeat region. MSP2 sequences fall into two distinct 
allelic families namely FC27 and 3D7 (IC-1) [117-120]. Within these allele-families, the 
central repeats vary in length, number and sequence among isolates. Allele-specific and 
length polymorphism in MSP2 has been used as the basis for high-resolution genotyping of 
P. falciparum isolates [121, 122].  
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MSP2 is a target of naturally acquired antibodies [123, 124] and antibodies are associated 
with protection against clinical malaria in some studies [125-128]. Longitudinal studies have 
suggested allele-specific antibody responses, with encountered strains not being observed in 
subsequent infections [129, 130], while others have shown that individuals can be re-infected 
with homologous strains [131]. The Combination B vaccine, which was composed of the 3D7 
alleles for MSP1, MSP2 and ring-associated erythrocyte surface antigen (RESA) was tested in 
Phase II trials in Papua New Guinea in the early 1990’s. This vaccine, which is discussed in 
more detail later, was shown to be efficacious, reducing parasite densities significantly with 
most of the activity attributed to MSP2 [6]. A combination vaccine, MSP1-C1 containing 
both the 3D7 and FC27 alleles has recently been tested but showed unacceptable 
reactogenicity due to the adjuvant used and the trial was terminated [132]. 
3.1.6 Merozoite Surface Protein 3 
MSP3, also known as Secreted Polymorphic Antigen associated with Merozoites (SPAM) is 
associated with the merozoite surface. It is secreted into the parasitophorous vacuole of the 
mature parasite (schizont) where it undergoes proteolytic cleavage [133-135]. Upon rupture 
of the infected erythrocyte, some MSP3 protein remains associated with the merozoite [133]. 
MSP3 contains three blocks of a polymorphic heptad repeat flanked by conserved sequences 
[133]. While initial studies reported limited polymorphism [134, 136] analysis of several 
isolates has revealed that the sequence is primarily dimorphic in nature with both point 
mutations and repeat variations in the N-terminal half of the protein with different alleles 
demonstrating variable antibody binding activity [137]. Antibodies produced in mice can 
inhibit parasite growth in vitro in co-operation with monocytes [135] but are allele-specific 
[138]. Furthermore, antibodies to different alleles in endemic human populations are 
individually associated with protection against clinical episodes [138]. Sequence data from 
natural parasite populations has confirmed that this antigen is under strong balancing 
selection and therefore a natural immune target [138].  
A MSP3 vaccine based on a long synthetic peptide (MSP3-LSP) covering a relatively 
conserved region (amino acids 181-276) from strain FC27 has been tested in Phase I trials in 
Switzerland and later in Burkina Faso and shown to be safe and immunogenic with a strong 
cytophilic response [45, 139]. Although the second trial was not designed specifically to test 
efficacy the number of clinical episodes was measured as a means to monitor safety. 
Comparison of two MSP3-LSP vaccinated groups (different adjuvants) compared to 
individuals that received the alternative vaccine (Hepatitis B) demonstrated that the 
incidence of clinical malaria was three to four-fold lower in the MSP3-LSP vaccine groups 
[45]. Interestingly however, the degree of protection wanes substantially during the follow 
up period of 60 days, suggesting that protection may be short-lived. The GMZ2 vaccine 
comprising a fusion protein containing conserved regions of MSP3 and Glutamate Rich 
Protein (GLURP) has also been confirmed as safe and immunogenic in Phase I trials [140] 
and Phase II trials are currently underway [51].  
3.1.7 175kDa Erythrocyte Binding Antigen (EBA175) 
The 175 kDa Erythrocyte Binding Antigen, EBA175, is found in the micronemes, which are 
located at the apical end of the merozoite [141, 142]. It is a parasite ligand that directly 
associates with its receptor, Glycophorin A on the surface of uninfected erythrocytes. This 
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occurs via an interaction between sialic acids and the Glycophorin A backbone [143, 144]. The 
cysteine-rich binding region (RII) is a 616 amino acid region consisting of two regions – F1 and 
F2, which are known as Duffy binding-like (DBL) domains named so as they are homologous 
to P. vivax Duffy binding protein, DBP. These domains are found in several other adhesion 
ligands of P. falciparum including Erythrocyte Membrane Protein 1 (PfEMP1). Antibodies to 
EBA175-RII can be induced by immunization in animal models by recombinant EBA175 
protein [143] and are acquired in humans naturally exposed to malaria [36, 145-147] and these 
antibodies can inhibit parasite invasion in vitro [142, 148]. Studies have suggested that EBA175 
alleles are maintained by immune selection [149] and high levels of haplotype diversity are 
present, most likely as a result of recombination [8]. However, because P. falciparum parasites 
can vary the use of EBA175 to evade antibodies [150], EBA175 could not be used alone but 
would need to be combined with other merozoite antigens.  
Vaccination of primates with the EBA175 vaccine candidate, EBA175-RII-NG, which is based 
on the 3D7 allele of RII, resulted in a significant decrease in parasite density after homologous 
challenge [151]. Clinical trials have proven the vaccines safety and shown that it produces 
antibody responses in vaccinated individuals. Furthermore, the serum of vaccinated 
individuals was shown to inhibit the binding of recombinant EBA175-RII to erythrocytes [152].  
3.1.8 Pfs25 and Pfs45/48  
The transmission blocking candidates Pfs25 and Pfs45/48 are found in the zygote/ookinte 
and gametocyte stages respectively. These antigens, which migrate as single and double 
bands respectively, are targets of antibodies that have been shown to block transmission of 
P. falciparum to the mosquito vector [153-156]. Pfs25 was cloned well before Pfs48/45 [157, 
158] and therefore is the only candidate for which a vaccine trial has been carried out. 
Preclinical development studies are underway for the latter antigen. The attraction of Pfs25 
as a vaccine candidate is that it is not expressed in the human host and has relatively limited 
polymorphism [159, 160]. It is therefore unlikely to be under the same immune pressures as 
other antigens, however one downside of this is that natural boosting may not occur unless 
long lived T-cell responses are elicited by the vaccine. Pfs48/45 gene knock out experiments 
demonstrate a key role in male fertility [161]. Anti-Pfs48/45 antibodies in individuals 
naturally exposed to malaria are associated with transmission blocking activity [162] and 
given that it is expressed within the human host it is likely to allow natural boosting of 
antibody responses. Pfs25 is relatively conserved [163] while Pfs48/45 shows high levels of 
diversity worldwide with evidence of diversifying selection and strong geographic 
structuring [8, 164, 165].  
The only vaccine trial of these two antigens that has been conducted is a phase I trial of the 
Pfs25 vaccine candidate. However it was halted due to unexpected adverse effects [166]. 
Preclinical studies have demonstrated a significant increase in the immune response of 
animal models, and immune-sera had a significant transmission blocking effect [167]. 
Further clinical trials are planned [51]. 
3.1.9 Other Plasmodium falciparum vaccine candidates  
There are several other malaria vaccine candidates currently under development which are 
based on well-known antigens, such as GLURP, which as mentioned above is being tested in 
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combination with MSP3 [140], Liver Stage Antigen 1 (LSA1) being developed as a 
component of the ME-TRAP vaccine [168] and as a single component vaccine [169]; and 
MSP4 [170]. More recently discovered antigens demonstrate significant potential as vaccine 
candidates including members of the Rh family of proteins (Rh1, 2a, 2b, 4 and 5) [171, 172] 
and the Rh-interacting protein, RIPr [173], Serine repeat antigen 5 (SERA5, reviewed in 
[174]); MSP6 [175], MSP7 [176] and the pregnancy-associated malaria vaccine candidate, 
var2csa [177-179]. For some of these antigens, diversity is a significant issue that needs to be 
evaluated. 
Combinations of antigens from different P. falciparum lifecycle stages have also been tested. 
Trials for Spf66, a synthetic combination of peptides from including CSP, MSP1 and two 
others of unknown origin have now been halted after it was shown to have no effect on 
malaria [180], NMRC-M3V-Ad-PfCA which is a combination of CSP and AMA1 and is 
currently in phase 2 trials in the USA [51], GMZ2 which was mentioned above (MSP3 and 
GLURP, [140]) and the EBA/Rh vaccine candidate, which consists of EBA175 (RIII-V) and 
Rh2a/b, Rh5 and RIPr binding regions [181]. This vaccine candidate is still undergoing 
preclinical testing and aims to target different invasion pathways used by the merozoite 
[172]. 
3.2 Plasmodium vivax 
The increasing recognition of the importance of Plasmodium vivax, both as a significant cause 
of severe malaria and as a major obstacle to malaria control and elimination has exposed 
some major gaps in our knowledge of this parasite [182]. The vaccine development pipeline 
is lagging well behind that of P.falciparum and while work is progressing on vaccines 
targeted at the P.vivax Duffy-binding protein (DBP, [183]), which has long had a human 
genetic correlate (Duffy negative individuals have a greatly reduced risk of infection) [184], 
relatively little has been done on the blood-stage antigens homologous to those being 
intensively tested for P.falciparum [39]. Underlying this lack of development is an urgent 
need to understand more about the biology of the transmission of the parasite, the extent of 
its diversity at a population level, and the mechanism of acquiring immunity to it.  
One major obstacle impeding P.vivax research is the fact that presently, P.vivax cannot be 
maintained in long-term culture or at high parasitaemias. In addition, infected individuals 
typically present with low parasitemia and therefore parasite material is less available than 
for P. falciparum [185]. Recombinant P.vivax proteins for use in immunoepidemiological 
studies and vaccine development therefore are often isolated from reference strains, such as 
Sal1 (Salvador).  
Many P. vivax vaccine candidates currently being investigated are orthologues of P. 
falciparum vaccine candidate antigens [38, 39]. However, these two species have distinct 
biological features, the most obvious being the ability of P. vivax to form dormant liver 
stages, and also their variable transmission in different regions across the globe. Therefore it 
is difficult to base conclusions for P.vivax, on what is known for P.falciparum. Many experts 
believe that a malaria vaccine will need to contain a combination of both P. falciparum and P. 
vivax antigens to be globally effective, since many regions of the world are burdened with 
both species [38].  
www.intechopen.com
 
Using Population Genetics to Guide Malaria Vaccine Design 
 
241 
Only two P.vivax vaccine candidates, the circumsporozoite surface protein (CSP) and the 
gametocyte antigen, Pvs25, have been tested in clinical trials to date [38]. However, a host of 
additional P.vivax proteins are currently under investigation as potential vaccine candidates, 
including PvDBP [38], PvTRAP [186], PvMSP-1 [187], PvAMA-1 [188]; and the transmission 
blocking candidate, Pvs28 [38]. Additional antigens identified as potential P.vivax vaccine 
candidates include PvMSP3, PvMSP4, PvMSP5 and PvRBPs I and II [38]. PvMSP9 has also 
been revealed as a promising vaccine candidate in recent studies [189]. 
4. Variant-specific immunity 
Naturally acquired immunity to malaria develops only after years of exposure to infection 
by Plasmodium parasites. The extensive genetic diversity that is characteristic of malaria 
surface antigens provides one explanation for this, especially because immune responses are 
variant-specific. Eventually, antibodies to all of the variants in the parasite population are 
acquired or reach a threshold whereby protection against clinical episodes is achieved 
(reviewed in [190]).  
4.1 Identifying targets of human immunity 
Numerous epidemiological studies have investigated the role of malarial antigens as 
natural targets of human immunity with conflicting estimates of their protective effect. 
While differences in study methodology, transmission intensity, and the rate of natural 
immunity acquisition [190, 191] will account for some of the discrepancies, parasite 
genetic diversity is likely to play a major role. This is because the prevalence of the major 
allelic types of specific antigens and subsequent acquisition of allele-specific immunity 
varies across populations.  
A recent systematic review and meta-analysis investigating the protective effect of antibody 
responses to merozoite antigens, highlighted the issues of genetic diversity in immuno-
epidemiological studies [192]. This review pooled all the published evidence for the 
association between anti-merozoite antibodies and the incidence of P. falciparum for each 
antigenic allele. For each allele, individual study estimates often showed large degrees of 
heterogeneity and comparing pooled estimates across alleles for the same antigen either 
showed similar (e.g. MSP1, MSP2) or very different (e.g. MSP119, MSP3, AMA1, GLURP) 
magnitudes of a protective effect.  
A major contributor to the heterogeneity in protective estimates is the fact that allele-specific 
antibody response to the strain causing the malaria episode was not measured in these 
studies. If antibody-mediated protection is largely allele-specific then the true causal 
protective effect will be underestimated in studies that do not use allele-specific P. falciparum 
outcomes. For example, meta-analysis of studies investigating the protective effects of anti-
MSP23D7 and MSP2FC27 responses showed no evidence of a reduced risk of symptomatic P. 
falciparum (all strains combined) [192]. Four studies included allele-specific endpoints; two 
studies in PNG showed protective MSP2 responses to homologous strains [125, 128] 
whereas studies in South America and Africa [193, 194], show no evidence of a protective 
effect of pre-existing MSP2 allele-specific immunity on clinical episodes with homologous 
parasites.  
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It is clear that the importance of allele-specific immunity to malaria has been understudied 
in sero-epidemiological studies. There is a real need to incorporate strain-specific responses 
and endpoints in immuno-epidemiological studies to address whether protective responses 
against particular antigens are strain-transcending or strain-specific. This research is 
imperative so we can elucidate whether sub-unit vaccines including only one allelic type 
might protect against a small subset of the parasite population and thus select for parasites 
bearing heterologous alleles. 
4.2 Vaccine trials and antigen polymorphism 
Significant sequence polymorphism is present in most of the vaccine antigens that are 
currently in clinical trials, as well as in many of the lead candidate antigens that are in pre-
clinical development. This includes P. falciparum antigens such as CSP (RTS,S vaccine), 
MSP1-42, MSP2, MSP3, AMA1, and P. vivax antigens, such as DBP [36]. Presently, there is 
only a very limited understanding of how sequence polymorphisms relate to antigenic 
diversity or the potential for polymorphisms to mediate vaccine escape. 
Different approaches can be taken to overcome antigenic diversity present in vaccine 
candidates. One approach is to include multiple alleles, or variants, of an antigen such that 
the vaccine-induced responses cover most of the different alleles circulating in a population; 
referred to as multivalent vaccines. This approach has been widely used in the development 
of vaccines for viral and bacterial pathogens. Examples include vaccines for Streptococcus 
pneumonia, Neisseria meningitidis, and influenza. Among malaria vaccines, multivalent 
vaccines are in development for several antigens including MSP2 [132] and AMA1 [195] of 
P. falciparum. The level of polymorphism seen among different candidate antigens varies 
substantially, being high for some candidate antigens, such as AMA1, compared to others, 
such as EBA175 [8]. Antigens that have a lower level of diversity may be more attractive 
candidates for vaccine development; however, multiple factors need to be considered in 
prioritising the many potential antigens for development [36]. An alternative approach is to 
design vaccine constructs that include a conserved region of the antigen so that vaccine-
induced responses would target epitopes common to all variants of the antigen. This 
approach is being taken for P. falciparum MSP3, whereby the vaccine antigen includes a 
conserved stretch of sequence (known as MSP3-LSP) towards the C-terminal end of MSP3 
and reportedly omits the highly polymorphic epitopes [196]. Interestingly however, recent 
population genetic surveys have shown that T-cell epitopes within MSP3-LSP are somewhat 
polymorphic [138].  
A well-known example of the importance of antigenic diversity in vaccine development is 
the phase I/IIb trial of the Combination B vaccine for P. falciparum malaria [6], which was 
mentioned earlier. The vaccine had significant efficacy in reducing parasite densities 
during follow-up and the anti-malarial effect of the vaccine is thought to be mediated 
primarily by responses to MSP2, rather than other components of the vaccine. Although 
MSP2 is polymorphic, nearly all sequences can be grouped into two allelic families, 3D7 
and FC27. The Combination B vaccine contained only the 3D7 form of MSP2 and, 
consequently, infections in vaccinated individuals were over-represented by FC27 allelic 
types. This implies that the vaccine only had substantial efficacy against infections 
containing the vaccine allele, 3D7. To address this, an MSP2 vaccine containing both of the 
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major allelic types is in development [132]. A more recent example of the challenge of 
antigenic diversity in malaria vaccines is AMA1. A phase II trial of a vaccine containing a 
single allele of P. falciparum AMA1 (3D7-allele) had no significant clinical efficacy when 
all malaria episodes were considered [46]. However, as was mentioned earlier, the vaccine 
demonstrated 68% efficacy against malaria episodes caused by AMA1 alleles that were 
similar in sequence to the vaccine allele. The development of approaches to overcome 
diversity in AMA1 and generate responses that give broad population coverage are 
ongoing. 
The most advanced vaccine in development, RTS,S, is based on a region of P. falciparum CSP 
[25]. Because CSP is polymorphic, an obvious question was whether diversity in CSP may 
explain the partial efficacy of the RTS,S vaccine. Analyses of infecting genotypes in one 
phase II trial of RTS,S suggested that this was not the case as there was no evidence of 
selection for infections containing non-vaccine genotypes among vaccinated versus control 
subjects [197, 198]. These findings highlight that although antigen polymorphism needs to 
be considered in vaccine development, it may not be a major issue for all vaccines. Clearly, 
there is a lot more we need to understand about the nature and specificity of responses and 
the importance of sequence diversity.  
There are a number of other promising antigens in pre-clinical development or early 
clinical trials where issues of polymorphisms have been explored. The leading P. vivax 
vaccine candidate, DBP [199] has significant polymorphism that appears to impact on the 
efficacy of inhibitory antibodies [200], and protective immunity shows a degree of strain-
specificity [201]. The erythrocyte binding region of the P. falciparum vaccine candidate 
EBA175, also has significant polymorphism [149, 202]. Interestingly, studies suggest that 
these polymorphisms have little impact on the efficacy of vaccine-induced inhibitory 
antibodies in vitro [203, 204]. However, the ability of P. falciparum to vary the expression 
and use of EBA175 during invasion may be an important means of immune evasion [150], 
which presents different challenges in vaccine design. Another example is the PfRh 
invasion ligand family. One member that appears to be an important target of acquired 
immunity, PfRh2, has significant polymorphism in the N-terminal region [171], but 
studies suggest it is possible to target a C-terminal conserved stretch of the protein in 
vaccine design [172]. The challenge of addressing diversity in vaccine development is 
greatest for PfEMP1, which is expressed on the surface of infected RBCs. PfEMP1 shows 
extreme sequence diversity (e.g. [205, 206]) and is encoded by a family of around 60 var 
genes per genome that enables clonal antigenic variation through expression of different 
PfEMP1 variants [207]. A vaccine trial in non-human primates showed strain-specific 
protective efficacy [208] and it is not clear how this extensive antigenic diversity can be 
overcome. However, one specific PfEMP1 variant, known as var2csa, plays a key role in 
placental infection [209] and may be a suitable target for a vaccine that helps protect 
pregnant women from the complications of malaria during pregnancy. Although this 
single variant has a high level of polymorphism [210], recent studies suggest the extent of 
antigenic diversity may not be high as there appear to be many shared epitopes that are 
common to different variants [211, 212], and antibodies that cross-react to different 
variants have been induced by vaccination [213, 214] and are acquired through natural 
exposure [211, 215] 
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5. How can population genetics inform malaria vaccine development? 
Population genetics is the study of allele frequency distributions and changes that occur in 
response to the four major forces of evolution: natural selection, genetic drift, mutation and 
gene flow [216]. All of the current malaria vaccine candidates are potential targets of 
positive balancing selection due to pressure from human immune responses. Balancing 
selection maintains alleles at low to medium frequencies and therefore no single allele is 
likely to provide broad protection [217]. Population genetic analyses can reveal insight into 
the extent and distribution of alleles and has been important in highlighting antigens as 
targets of natural immunity [218, 219]. 
Scores of population genetic surveys have been conducted on malaria vaccine 
candidates, including isolates from countries in every major malaria-endemic corner of 
the world. However, the data has generally not been used in the formulation of malaria 
candidate vaccines. Vaccine developers have included alleles isolated from well-
characterised reference strains, 3D7 (and its parent NF54, origin unknown), FVO 
(Vietnam) or FC27 (Papua New Guinea). However, amongst the substantial sequence 
data available for many countries for several leading malaria vaccine antigens, these 
alleles are either completely absent or found at low frequencies among naturally 
circulating parasites (Figure 1, [8]).  
A recent metapopulation genetic analysis has summarised the known diversity of twelve 
leading malaria vaccine candidates [8]. After compiling all available published population 
data on malaria vaccine candidates, either currently in vaccine trials or in preclinical 
development, a database of almost 5000 sequences was used to investigate the range and 
distribution of diversity. Only non-synonymous polymorphisms were investigated as 
synonymous polymorphisms do not change the protein structure and are therefore 
antigenically irrelevant. Table 1 summarises the results observed for the ten antigens 
analysed in this study, as well as other P. falciparum and P. vivax antigens that are leading 
malaria vaccine candidates. 
The data presented in Table 1 demonstrates that the majority of current malaria vaccine 
candidate antigens have many distinct haplotypes and this emphasises the problem of 
diversity in developing a broadly effective malaria vaccine [35]. However, without 
knowledge of this natural diversity it will be difficult to assess vaccine trials to the full 
extent. In addition, for genes encoding merozoite antigens including AMA1, EBA175 and 
MSPs 1-4 the full breadth of diversity was present in all populations with no evidence of 
geographic population structure, suggesting that they are under strong immune selection. 
However, genes encoding the non-merozoite antigens including CSP, TRAP, LSA1 and 
Pfs48/45 showed variable levels of diversity, which were related to transmission levels, 
and there was evidence of geographic population structure [8]. The consequence of this 
contrasting distribution of diversity for malaria vaccine design is that a diversity-covering 
vaccine may be possible for merozoite antigens but for the non-merozoite antigens 
identifying common alleles across all populations will be difficult. Nevertheless, diversity 
in the non-merozoite antigens does not appear to be primarily structured by immune 
selection, and therefore may not be as immunologically relevant as that for the merozoite 
antigens. 
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Antigen Expression Domain Continents Countries
Total isolates 
sampled 
(range)
Total 
haplotypes 
(range) References 
Plasmodium 
falciparuma 
CSP sporozoite C-terminal 3 13 604 (9-143) 71 (3-20) 
reviewed in 
[8] 
TRAP sporozoite N-terminal 2 3 100 (8-48) 84 (8-37) 
reviewed in 
[8] 
LSA1 liver stage N-terminal 3 4 74 (10-22) 13 (3-7) 
reviewed in 
[8] 
GLURP 
sporozoite/
gametocyte Region 0 3 3 48 (9-11) 22 (2-9) 
reviewed in 
[8] 
AMA1 merozoite Domain I 3 11 572 (8-162) 181 (6-68) 
reviewed in 
[8] 
EBA175 merozoite Region II 2 3 135 (30-48) 51 (15-23) 
reviewed in 
[8] 
MSP1 merozoite MSP119 3 11 
2237 (18-
1368) 20 (1-15) 
reviewed in 
[8] 
MSP2 merozoite 
Blocks 2 and 
3 2 3 392 (n.d) 275 (n.r.) 
reviewed in 
[8] 
MSP3 merozoite 
Repeat 
region 2 2 124 (75-86) 21 (9-12) 
reviewed in 
[8] 
MSP4 merozoite Full length 2 4 142 (12-42) 47 (9-23) 
reviewed in 
[8] 
MSP3/6 merozoite 1 2 117(51-66) n.r. [218, 219] 
Rh2 merozoite 
Binding 
region 1 1 33 (15) n.r. (13) [171] 
Rh4 merozoite
Binding 
region 1 1 23 (12) 9 (4)
Reiling et al. 
unpublished 
data 
Pfs48/45 gametocyte Full length 3 4 55 (9-15) 19 (2-8)
reviewed in 
[8] 
Pfs28 ookinete no population data available
var2csa trophozoite DBL3 2 3 124 (15-54) n.r. [211] 
Plasmodium 
vivaxb 
CSP pre-eryth 
Central 
repeat 2 2 168 (31-137) n.r. (13-25) [220, 221] 
TRAP pre-eryth 
Regions II-
IV 2 2 74 (37-37) 54 (n.r.) [222] 
AMA1 merozoite Full lengthc 2 2 96 (23-73) n.r. (15-18) [223] [224] 
MSP1 merozoite Full lengthc 2 7 196 (40-116) n.r. (12-31) [187, 225] 
DBP merozoite Region II 2 8 675 (11-123) n.r. (9-73) [226] 
Pvs28 ookinete All 1 1 20 2 [227] 
Pvs25 ookinete All 1 1 30 4 [227] 
a.Total includes both natural populations and other isolates, range includes only natural populations; b. 
Total (range) includes only natural populations; c.Individual domains also analysed, data not shown; 
n.r. result not available. 
Table 1. Summary of population genetic data for leading malaria vaccine candidates 
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5.1 Sampling diversity 
An important consideration when investigating the genetic diversity of a vaccine candidate 
is the origin and number of samples required to obtain reliable allele frequency estimates. In 
early studies, only a handful of parasite isolates from diverse geographic origins were used 
to investigate diversity, however more recently a number of investigations on larger 
numbers of locally circulating field isolates which can represent natural parasite 
populations, have been completed (reviewed in [8], Table 1). While a geographically 
disparate sampling approach can provide insights into levels of polymorphism, immune 
selection and can allow the extent of diversity to be predicted, it cannot provide reliable 
information on allele frequencies. The latter approach is more appropriate if data will be 
used for prioritizing common alleles for vaccine development. However it is critical that 
large sample sizes of a minimum of 30-50 isolates be used to obtain a reliable estimate of 
diversity and values approaching natural allele frequencies. Once defined, natural allele 
frequencies can provide an indication of the minimum proportion of the parasite population 
that would be covered by a particular vaccine formulation. Further analysis, discussed 
below, can identify relationships amongst alleles and therefore the potential for cross-
reactivity between distinct alleles. 
5.2 Defining the extent of diversity 
In population genetics, the extent of diversity at a defined locus is measured using a number 
of different statistics. These include statistics that are simple to estimate: e.g. the number of 
alleles or haplotypes and more complex statistics such as the allelic richness, which is 
normalised for sample size [228] and therefore is useful to compare among populations if 
samples sizes vary considerably. Other statistics include the nucleotide diversity (pi), which 
is the average proportion of sites that are polymorphic within a group of sequences; the 
average number of differences and the expected heterozygosity, all of which can be easily 
calculated with the help of a myriad of population genetic software (reviewed in [229]). The 
most informative statistics for vaccine design includes the numbers of alleles or haplotypes 
that need to be considered in developing a broadly efficacious malaria vaccine. For example 
if we consider the data in Table 1, some antigens have larger numbers of haplotypes than 
others, such as CSP with 71 haplotypes while MSP3 has only 21 even though the two 
datasets were similar in size, showing that CSP is the more diverse antigen [8]. 
5.3 Defining the distribution of diversity  
5.3.1 Allele and haplotype frequencies 
Knowledge of the distribution of alleles and haplotypes (variants) is critical both for vaccine 
design and for monitoring the effects of vaccine trials. In trials for vaccine candidate 
antigens with allele-specific immunity, a high frequency variant has a higher likelihood of 
resulting in a protective effect than a low frequency variant (if the vaccine construct covers 
polymorphic regions). Furthermore, the identification of geographically distinct population 
structures is an indication that variants may be present at different frequencies. In this 
situation, it is possible that a vaccine based on a common allele in one population that is rare 
in another population, may have differential effects across the two populations. Similarly, if 
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a vaccine is based on a variant that is found at low frequencies at a testing site, the positive 
effects of variant-specific immunity may be dampened by infection with parasites carrying 
non-vaccine alleles. The vaccine may then be interpreted as being non-protective, unless 
variant-specific end-points are included by genotyping post-vaccine infections. Another 
important consideration in this scenario is that the statistical power to measure variant-
specific efficacy will be limited with only a small number of infections carrying the vaccine 
allele. 
The importance of allele/haplotype frequencies in vaccine design has been demonstrated 
by a study that measured MSP119 diversity at a vaccine-testing site in Mali. High 
throughput genotyping of six common MSP119 polymorphisms in more than 2000 isolates 
showed that there were two highly prevalent haplotypes (FVO, 46% and FUP, 36%) 
whereas the majority of the haplotypes were relatively rare (<10%). The common 
haplotypes remained common over long periods of time (>44% and 34% respectively), 
with fluctuations that could be explained by frequency dependant selection [113]. The 
vaccine haplotype, 3D7, was the third most common, being found at a frequency of 16% 
(14-18%) throughout the study period. The authors concluded that the previous MSP119 
vaccine trial [114] probably failed as a result of a lack of parasites harbouring 3D7 MSP119 
haplotypes. Studies have investigated changes in vaccine antigen haplotype frequencies 
over time under natural conditions ([93, 230, 231]) but there have been e.g. relatively few 
during vaccine trials [98, 115]. More studies are needed to monitor fluctuations that occur 
in parasite populations over time, especially under the influence of natural immune or 
vaccine-mediated selection.  
5.3.2 Clustering patterns 
Cluster analyses have been used to identify population substructure within a given sample 
to understand the underlying population biology of P. falciparum [232]. This analysis has 
also been adapted to understand relationships among haplotypes of several malaria vaccine 
candidates [8, 91, 92, 226]. A study of 150 AMA1 sequences by Xin Zhuan Su and colleagues 
demonstrated that they clustered into six distinct subgroups. Some evidence was also 
presented that sera from rabbits immunized with AMA1 variants from one cluster tended to 
inhibit invasion of parasite isolates carrying sequences from the same cluster, but were less 
active against those from other clusters, suggesting that different clusters contain 
immunologically distinct sequences [91]. Later studies, including 506 AMA1 domain I 
sequences analysed have suggested up to 16 clusters [92]. Although the full utility of 
clustering patterns is yet to be confirmed, they may be used as a guide to select 
representative variants to cover diversity as well as to predict the effects of a vaccine trial 
within a defined geographic area. This is particularly important because different malaria 
antigens show different clustering patterns ([8], Figure 2). If clusters represent 
immunologically distinct subgroups, the patterns observed in Figure 2 suggest that 
vaccination with CSP would be significantly more effective in Africa and parts of the 
Americas, whereas for MSP1 the effects would be similar among many populations. 
Different polymorphisms have varying immunological significance [85, 97] and a better 
understanding of the relationship between polymorphisms and antigenic diversity will help 
advance the development of clustering algorithms.  
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Fig. 2. Cluster analysis of sequences for (A) the pre-erythrocytic antigen, CSP and (B) the 
merozoite antigen, MSP119 . Non-synonymous haplotypes were submitted to cluster analysis 
using STRUCTURE software [233]. Each bar represents the mean membership co-efficient for the 
parasite population of each country and colours represent the mean membership to each of the 
clusters. Vaccine alleles include CSP: 3D7; MSP119: 3D7, FVO or FC27. Figure adapted from [8]. 
5.3.3 Networks 
Network analysis originated as a mathematical tool to understand social relationships and 
has been used to study the transmission of infectious diseases [234]. In population genetics, 
it has been adapted to explore relationships among sequences by linking haplotypes that are 
identical at a predefined proportion of polymorphic sites [8, 235]. As each haplotype (node) 
may have multiple connections (edges), this analysis has the potential to define not only 
distinct clusters or subgroups of highly related sequences but also the relationships among 
them. Furthermore, it can identify the location of less frequently observed admixed 
haplotypes in the network, which may represent novel recombinants. Barry et al. [8] have 
explored the distribution of haplotypes using network analysis and found that the network 
was concordant with clustering patterns for ten leading malaria vaccine antigens (Figure 3 
shows the results for AMA1 as an example). In addition, they demonstrated that haplotypes  
 
Fig. 3. Network of AMA1 (domain I) sequences. Each node (circle) represents a haplotype, 
shaded in colour to highlight cluster-membership or white for admixed haplotypes (as 
defined by the Structure analysis discussed above [233]). Nodes are tied by edges (black 
lines) demonstrating that they share a predefined threshold of 48 nsSNPs. Admixed 
haplotypes originating from isolates with unknown origin are shaded in white (unless they 
were vaccine haplotypes). Adapted from [8]. 
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that were identified as “admixed” in the cluster analysis (i.e. <75% of sequences assigned 
into any one cluster), often formed connections between one or more lobes of the network 
suggesting that these represent novel recombinants resulting from exchange between 
sequences from the linked clusters. Such recombinants might allow evasion of naturally 
acquired- or vaccine-mediated immune responses if vaccine formulations were comprised 
only of haplotypes from distinct subgroups or clusters. Network analysis will allow shifts in 
the proportion of haplotypes within each cluster and admixed/recombinant haplotypes to 
be monitored during vaccine trials.  
5.4 Immune selection 
Population genetic analyses can identify signatures of balancing selection in loci that are 
targeted by natural immune responses and therefore allow vaccine candidates to be ranked 
[66, 218, 219, 236]. While data from geographically diverse isolates can be useful, the ability 
to identify balancing selection is strengthened by allele frequency data from natural parasite 
populations [237]. Comparative studies, investigating polymorphism and allele frequencies 
by deep population sampling of several novel vaccine candidates have been done [218, 219, 
224, 237, 238]. These have demonstrated the relative levels of balancing selection and 
therefore whether particular candidates are stronger immune targets than others, but may 
also partially reflect the tolerance of a particular antigen to high levels of mutation.  
Balancing selection can be measured using a variety of different statistics, however the 
Hudson Kreitman Aguade ratio (HKAr), which is determined by calculating levels of 
divergence between species and dividing by the amount of diversity within a species [239] 
has been shown to be most informative for assessing selection in any dataset, including 
small numbers of isolates from diverse geographic locations. However, this also relies on the 
availability of sequences from the most closely related species for which genome data is 
available, namely Plasmodium reichenowi. Additional P. reichenowi isolates have been 
collected by researchers and may also be used to obtain further sequence data to increase the 
reliability of this statistic [240]. Another statistic that has proven to be reliable for predicting 
balancing selection, is Tajima’s D, which identifies departures from neutrality by measuring 
the number of polymorphic sites (S) in relation to the nucleotide diversity (pi) [241]. Tajima’s 
D requires allele frequency data and therefore can only be effectively used on population 
samples, with large sample sizes (>50 isolates) being the most informative [218].  
5.5 Credentialing polymorphisms 
It is clear that some antigens such as AMA1 and CSP have many polymorphic sites, while 
others such as EBA175 and MSP4 remain relatively conserved [8]. However, this is probably 
more a reflection of functional constraints or degree of immune exposure, than indicating 
their capacity to be an effective vaccine candidate. The challenge is how to determine which 
polymorphisms will be critical to vaccine design. Investigators have used different 
approaches to identify antigenically relevant polymorphisms, including three-dimensional 
structural modelling, immunological assays and mutational analysis [91, 97]. However, 
population genetic data - which may be easier to collect - can be highly informative.  
When choosing which polymorphisms to consider for vaccine design it is important to 
define the allele frequencies for each polymorphic site. If the minor allele frequency (MAF) 
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is <10%, at least 90% of isolates will carry the predominant allele, and therefore a vaccine 
candidate carrying the major allele will target the majority of the parasite population. 
Mapping regions of significant balancing selection (where allele frequencies will be low-
medium) will identify regions that have accumulated polymorphisms as a result of being 
directly targeted by the immune response [236]. These analyses can help identify regions 
that are targets of functional immune responses. The analysis can be done by sliding 
window analyses of Tajima’s D or measuring the HKAr for different protein domains. As 
balancing selection maintains balanced allele frequencies across different populations, it is 
also possible to use the interpopulation differentiation statistic, Wrights FST to measure 
differences in allele frequencies between populations. A low and insignificant Wrights FST 
value will demonstrate that allele frequencies are similar among populations and 
polymorphic regions potentially associated with immune escape [236, 242]. An additional 
important approach to determine key polymorphisms is by monitoring longitudinal 
infection dynamics in cohort studies, which may include vaccine trials [92]. If specific 
polymorphisms allow immune escape, then subsequent infections will carry alternative 
alleles to those of previous infections. Similarly, in vaccine trials, post-vaccination infections 
can be monitored for the presence of vaccine alleles. Antigenicity can then be determined by 
comparing allele frequencies in the vaccinated and control groups.  
6. Conclusion: The way forward  
The malaria vaccine development pipeline has suffered many setbacks and complications 
over the decades since the first malaria vaccine was trialed. Nevertheless, it is our opinion 
that with carefully planned vaccine trials and an understanding of naturally circulating 
parasite diversity, made possible through technological advances in next generation 
sequencing and dedicated bioinformatics efforts, a broadly effective subunit malaria vaccine 
is achievable. With respect to developing such a vaccine we put forward the following 
recommendations for the design and testing of the next generation of malaria vaccines: 
iv. Prioritise vaccine candidates: Many malaria vaccine candidate antigens have reached 
vaccine trials simply because they were discovered first. Genome sequencing and 
“omic” technologies have now identified several antigens that may have greater 
potential to induce protective immunity to a wide variety of parasite strains than these 
more traditional candidates. As the pipeline to clinical trials and eventual licensing is an 
arduous and vastly expensive journey, a thorough review of all candidates including 
those recently discovered and also in development needs to be done to identify those 
with the greatest potential to elicit protective immunity against malaria. 
v. Prioritise vaccine alleles: Dozens of population genetic studies have highlighted the 
issue of high levels of genetic diversity in candidate antigens and the low prevalence of 
the vaccine alleles currently being used, in natural parasite populations. Researchers 
now have the opportunity to mine already compiled datasets (e.g. [8]) or to rapidly 
sequence large numbers of field samples in vaccine testing sites to identify high 
frequency alleles for testing in single or multivalent vaccines. Notably, for a large 
number of leading malaria vaccine candidates under strong balancing selection, these 
alleles may be common across populations.    
vi. Allele-specific endpoints for vaccine trials: Few malaria vaccine trials have evaluated 
allele frequencies either before, during, or after vaccine trials have taken place and 
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therefore it is not possible to assess whether any allele-specific protection has been 
induced in individuals receiving the vaccine. Given the relatively low cost (compared to 
conducting a vaccine trial) and ready availability of high throughput genotyping and 
NextGen sequencing technologies, this step should certainly be included in future 
vaccine trials and could even be done in retrospect if samples are still available. 
However, it is important to note that in some trials where the allele used to formulate 
the vaccine is found at low frequencies in the testing site, sample size may be too low to 
evaluate any protective effects. 
vii. Parasite population monitoring: Even after an effective vaccine(s) has been developed 
and rolled out, sustained and intensive surveillance efforts will be essential to monitor 
population allele frequencies on a regular basis. This will identify significant 
fluctuations that might impact on vaccine efficacy or newly emerging alleles that may 
allow antigenic escape. With data obtained through such a surveillance system, 
formulations may then be adapted n a manner analogous to the Influenza vaccine, to 
ensure continued protection against malaria. 
A broadly effective malaria vaccine continues to be one of the most sought after strategies in 
the fight against malaria, however the diversity of many of the parasite antigens currently 
being considered as subunit vaccine candidates is an obstacle that must be overcome. 
Natural malaria parasite populations are complex and dynamic communities, but modern 
molecular and analysis technologies are providing new ways to understand them. It is 
therefore important that researchers consider using population genetics to inform malaria 
vaccine development from target discovery through to vaccine design and to assess the 
effects of clinical trials.  
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